Investment Thesis
Maze Therapeutics maintains a fortress balance sheet with $198.8M cash and 0.11x debt-to-equity, providing sufficient runway for operations. However, the company is operationally distressed with operating losses of $26.6M exceeding revenue of $20M, producing a -132.8% operating margin and -$39.1M negative operating cash flow. Investment thesis hinges on unproven ability to monetize commercialization effectively.
Strengths
- Exceptional balance sheet strength: $341.7M stockholders equity with only $38.8M long-term debt provides 5+ years operational runway
- Fortress liquidity with $198.8M cash and 17.88x current ratio eliminates near-term solvency risk
- $20M revenue demonstrates successful transition from pre-clinical to commercialization stage
- Conservative capital structure minimizes financial distress risk and dilution concerns
Risks
- Severe profitability crisis: operating losses ($26.6M) exceed revenue ($20M) by 33%, indicating fundamentally broken unit economics or excessive overhead
- Negative operating cash flow of -$39.1M combined with -121.0% net margin shows operations cannot self-sustain despite commercialization
- Missing gross profit data obscures whether product margins are viable or if SG&A burden is excessive
- Cash depletion at current burn rate (~$39M annually) requires profitability inflection within 5 years
- No evidence of path to operational breakeven or profitability trend improvement in available data
Key Metrics to Watch
- Operating cash flow recovery and inflection to positive (critical survival metric)
- Operating expense ratio trend relative to revenue growth (must narrow significantly)
- Gross margin data disclosure (indicates product-level viability)
- Revenue growth acceleration needed to exceed operating expense growth
- Quarterly burn rate trend and updated cash runway estimates
Financial Metrics
Revenue
20.0M
Net Income
-24.2M
EPS (Diluted)
$-0.45
Free Cash Flow
-39.2M
Total Assets
419.7M
Cash
198.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-132.8%
Net Margin
-121.0%
ROE
-7.1%
ROA
-5.8%
FCF Margin
-196.0%
Balance Sheet & Liquidity
Current Ratio
17.88x
Quick Ratio
17.88x
Debt/Equity
0.11x
Debt/Assets
18.6%
Interest Coverage
N/A
Long-term Debt
38.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:45:06.973438 |
Data as of: 2026-03-31 |
Powered by Claude AI